{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Cancer", "name": "subject", "rank": "2", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/03/12/opinion/cancer-drug-dosing.html", "document_type": "article", "byline": [], "type_of_material": "Letter", "multimedia": [], "section_name": "Opinion", "word_count": "156", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The Pharmaceutical Research and Manufacturers of America discusses the regulatory barriers to getting product modifications to market.", "pub_date": "2016-03-12T00:00:00Z", "news_desk": "Letters", "headline": {"kicker": "Letter", "print_headline": "Cancer Drug Dosing", "main": "Cancer Drug Dosing", "content_kicker": "Letter"}, "print_page": null, "snippet": "The Pharmaceutical Research and Manufacturers of America discusses the regulatory barriers to getting product modifications to market.", "_id": "56e3375438f0d81b768a681b", "slideshow_credits": null, "abstract": null}